Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Banner naproxen petition

This article was originally published in The Tan Sheet

Executive Summary

Banner Pharmacaps requests FDA allow filing of ANDA for naproxen sodium softgel capsules with same indication as Bayer's Aleve but different dosage form. In recent citizen petition to agency, Banner notes proposed naproxen softgel contains same active ingredient, same strength and same route of administration as Aleve tablets, will be labeled with same conditions of use but will differ with respect to dosage form, inactive ingredients and manufacturer contact information. High Point, N.C.-based firm recently received FDA approval for softgel version of Wyeth's Advil Liqui-Gels (1"The Tan Sheet" Oct. 28, 2002, In Brief). Leiner will package, market the 200 mg ibuprofen softgels in 20-, 40-, 80-, 135-, 200-count packages, as well as twinpacks of the 135-count for club outlets, generic firm says Nov. 14...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel